Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 57

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 57
---
 be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor with respect to certain civil liabilities, including liabilities under the Securities Act. We estimate that the total expenses for the offering, excluding compensation payable to Cantor under the terms of the Controlled Equity Offering SMSales Agreement, will be approximately $96,146.

This offering of common stock pursuant to this prospectus will terminate upon the earlier of (i) the sale of all common stock provided for in this prospectus, or (ii) termination of the Controlled Equity Offering SMSales Agreement as permitted therein.

This summary of the material provisions of the Controlled Equity Offering SMSales Agreement does not purport to be a complete statement of its terms and conditions. A copy of the Controlled Equity Offering SMSales Agreement is filed with the SEC and are incorporated by reference into the registration statement of which this prospectus is a part. See “Where You Can Find More Information” below.

Cantor and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M under the Exchange Act, Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under this prospectus.

This prospectus in electronic format may be made available on a website maintained by Cantor and Cantor may distribute this prospectus electronically.

| S-12 |

<div align='center'>LEGAL MATTERS</div>

The validity of the issuance of the common stock offered by this prospectus will be passed upon for us by Ellenoff Grossman & Schole LLP, New York, New York. Cantor is being represented in connection with this offering by Duane Morris LLP, New York, New York.

<div align='center'>EXPERTS</div>

The consolidated financial statements of Anixa Biosciences, Inc. and subsidiaries as of and for the years ended October 31, 2024 and 2023 have been incorporated by reference in the registration statement in reliance upon the report of Haskell & White LLP, independent registered public accounting firm, and upon the authority of said firm as experts in accounting and auditing.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospect